SecBot SecBot
SECBOTREPLAY Home › Report › KPTI

KPTI · Karyopharm announced submission of an sNDA to the FDA seeking…

Karyopharm Therapeutics Inc. · 8-K filed Aug 31, 2026 at 08:08 ET

At the news

BULLISHIMPACT 6/10

8-K filed Aug 31, 2026 at 08:08 ET

Karyopharm announced submission of an sNDA to the FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for myelofibrosis, based on Phase 3 SENTRY trial data showing a promising overall survival signal. Priority Review was requested, which could yield a six-month review cycle. FDA acceptance and review timeline decisions are expected in Q4 2026.

  • sNDA submitted for XPOVIO (selinexor) + ruxolitinib in myelofibrosis under Accelerated Approval pathway
  • Priority Review requested; if granted, review period would be approximately six months
  • FDA decision on sNDA filing acceptance and review timelines expected in Q4 2026
  • Submission based on Phase 3 SENTRY trial data with a positive benefit-risk profile and overall survival signal

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access